Propel Therapeutics

What Propel Therapeutics does

Propel Therapeutics is a physician-led ketamine therapy and psychedelic wellness clinic based in Sacramento, California, founded in 2020 by triple board-certified psychiatrist Dr. Christopher Fischer and board-certified anesthesiologist Dr. Sofia Peeva. The clinic's core offering is intravenous (IV) ketamine infusion therapy paired with Ketamine-Assisted Psychotherapy (KAP), delivered in purpose-built immersive environment rooms that the company describes as unique among Sacramento ketamine providers. Propel treats patients with treatment-resistant depression, anxiety, PTSD, OCD, bipolar and postpartum depression, suicidal ideation, and chronic pain conditions such as fibromyalgia, CRPS, and diabetic neuropathy, using an 8-week induction protocol followed by maintenance sessions.

The business operates on a professional-services revenue model, charging per infusion session plus KAP integration and accepting out-of-network insurance reimbursement for PPO plans, HSA/FSA funds, and third-party healthcare financing through CareCredit and Advance Care Card. Beyond ketamine, the clinic has diversified into semaglutide (GLP-1) weight management injections, NAD+ infusion therapy, functional mushroom supplements, and a forensic psychiatry service line leveraging Dr. Fischer's triple board certification. Patient progress is tracked through the Osmind platform, which also supports out-of-network insurance claim submission.

The go-to-market is sales-led and local: direct patient acquisition via free 15-minute consultations, content marketing (blog, podcasts, videos), organic social media on Instagram, Facebook, and LinkedIn, and a curated preferred-partner referral network of regional therapists and psychiatrists across the Sacramento metropolitan area and Northern California. Propel is a private, owner-operated medical practice with 1–10 employees, a single clinic location at 1010 Hurley Way, Suite 140, Sacramento, and no disclosed institutional funding.

Name

Propel Therapeutics

Legal name

Propel Therapeutics

Website

https://propeltherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Propel Therapeutics is a Sacramento-based ketamine therapy and psychedelic wellness clinic offering IV ketamine infusions paired with ketamine-assisted psychotherapy for treatment-resistant depression, PTSD, anxiety, and chronic pain, along with GLP-1, NAD+, and forensic psychiatry services.

Ownership category

akta.pro rank

Product category

Ketamine Therapy and Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Outpatient Mental Health and Substance Abuse Centers (62142)

SIC

Services-Nursing & Personal Care Facilities (8050)

akta.pro primary industry

Outpatient Substance Use Disorder (SUD) Treatment Programs (HLAFABAD)

Keywords

• Ketamine infusion therapy
• Ketamine-assisted psychotherapy
• Treatment-resistant depression
• Chronic pain management
• Forensic psychiatry services

Headquarters

HQ city

Sacramento

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Ketamine Infusion Therapy: IV ketamine infusions administered in clinic setting, paired with ketamine-assisted psychotherapy. Treatment involves an 8-week induction program with multiple sessions, followed by maintenance treatment.
2. Semaglutide Injections: GLP-1 receptor agonist injections for weight management and diabetes, prescribed as part of broader treatment plans including dietary modifications.
3. Forensic Psychiatry Services: Expert psychiatric testimony and evaluations for legal matters including competency evaluations, criminal responsibility, and personal injury cases.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Propel Therapeutics is a Sacramento ketamine therapy clinic that administers intravenous ketamine infusions paired with ketamine-assisted psychotherapy (KAP) to treat treatment-resistant depression, anxiety, PTSD, OCD, bipolar and postpartum depression, suicidal ideation, and chronic pain conditions such as fibromyalgia, neuropathy, CRPS, and post-herpetic neuralgia. The clinic also provides forensic psychiatric evaluations and expert testimony, semaglutide injections for weight management, NAD+ infusion therapy, and functional mushroom supplements, delivered in immersive environment rooms under medical supervision.

Product overview

Propel Therapeutics is a psychedelic wellness center and ketamine therapy clinic providing ketamine-assisted psychotherapy (KAP) and intravenous ketamine infusion therapy for mental health conditions (depression, anxiety, PTSD, OCD, bipolar depression, postpartum depression, suicidal ideation) and chronic pain conditions (fibromyalgia, diabetic neuropathy, CRPS, post-amputation pain, cancer pain, peripheral neuropathy, post-herpetic neuralgia). The clinic is led by board-certified psychiatrists and anesthesiologists and pairs every ketamine infusion with integration psychotherapy. The service portfolio also includes forensic psychiatry evaluations by Dr. Fischer, semaglutide injections for weight management, functional mushroom supplements, and NAD+ infusion therapy. All treatments are delivered in immersive, calming environment rooms with medical monitoring, using the Osmind Platform for patient progress tracking and out-of-network insurance claims submission.

Differentiator

Problem solved

Functional benefit

Products and services

• Ketamine Infusion Therapy Intravenous ketamine infusion therapy administered in an immersive, relaxing environment under medical supervision, used to treat mental health conditions (depression, anxiety, PTSD, OCD) and chronic pain conditions (fibromyalgia, neuropathy, CRPS). IV is the gold-standard delivery route (100% bioavailability, titratable), with approximately 45–60 minutes per session and a typical 8-week induction course of once-weekly sessions.
• Ketamine-Assisted Psychotherapy (KAP) Psychotherapy sessions paired with ketamine infusions, led by a trained therapist, to help patients anchor insights, process emotions and trauma, prevent overwhelm, and integrate the ketamine experience into lasting behavioral change. Integration sessions and group integration offerings are available to support sustained neuroplasticity-driven transformation.
• Forensic Psychiatry Services Comprehensive forensic psychiatric evaluations and expert witness testimony provided by Dr. Christopher Fischer, M.D. for both criminal and civil legal matters, including competency evaluations, criminal responsibility assessments, personal injury evaluations, disability assessments, and mitigation assessments.
• Semaglutide Injections (GLP-1) Glucagon-like peptide-1 (GLP-1) receptor agonist injections for weight management and type 2 diabetes treatment, slowing gastric emptying to increase fullness and reduce appetite as part of a broader treatment plan including dietary modifications and exercise; patients can lose up to 15% of body weight.
• Functional Mushrooms Supplements Supplements containing functional mushroom varieties (e.g., reishi, lion's mane, cordyceps, chaga, shiitake) marketed for immune support, cognitive health, and stress management, aligned with the clinic's holistic wellness approach.
• NAD+ Infusion Therapy NAD+ (nicotinamide adenine dinucleotide) intravenous infusion therapy offered by infusion nurse Jackie Noble, RN, aimed at supporting cellular health, mental clarity, and emotional resilience.

Quantifiable outcome

• 85% of patients experience symptom relief after 4-8 ketamine sessions
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and secondary.

• Heart Space PsychotherapycoreStrategic or Co-development PartnerAndreina Cheema, LMFT provides ketamine integration psychotherapy and somatic therapy services. Partners with Propel for patient referrals and offers holistic trauma-informed therapy.
• Brain Garden PsychiatrycoreStrategic or Co-development PartnerMedication management partner offering psychiatric services for patients. Provides comprehensive mental health care coordination with ketamine treatment.
• Bonnie Miller LMFTsecondaryStrategic or Co-development PartnerLicensed Marriage and Family Therapist with Ketamine-Assisted Psychotherapy training at Polaris Insight Center San Francisco. Provides integration therapy and trauma-informed care.
• Lemke Health Partners / Jessica Del Pozo PHDsecondaryStrategic or Co-development PartnerLicensed clinical psychologist certified in Psychedelic-Assisted-Therapy (PAT) with advanced KAP training. Located in Sierra foothills of Northern California.
• OsmindcoreTechnology or IntegrationTechnology platform partnership for patient progress tracking, mood scores, validated questionnaires, and out-of-network insurance claim submission. Propel is listed as Osmind clinic partner.
• CareCreditcoreOthersHealthcare credit card offering 6 months interest-free financing for ketamine therapy treatments, helping patients manage treatment costs.
• Advance Care CardcoreOthersHealthcare financing platform matching patients with credit cards offering 0% APR for 12-14 months interest-free grace period for ketamine therapy costs.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Klarisana: Multi-location ketamine infusion clinic chain focused on treatment-resistant depression, PTSD, and chronic pain — comparable clinical model, dosing protocol, and physician-led practice structure.
• The Ketamine Clinic: Outpatient ketamine infusion clinic treating depression, anxiety, PTSD, and chronic pain under physician supervision — directly comparable service catalog and delivery model.
• Actify Neurotherapies: Outpatient ketamine and neurotherapy clinic network delivering IV/IM ketamine infusion therapy for mood and pain disorders — comparable patient mix, infusion-led delivery, and regional clinic model.
• California Center for Ketamine Therapy: Outpatient ketamine infusion clinic operating in California treating depression, PTSD, and chronic pain — directly comparable in geography, clinical model, and patient population to Propel Therapeutics.

Emerging players

• Nue Life: Ketamine and psychedelic-assisted therapy provider with a digital/telehealth-enabled intake and a clinical infusion component — overlapping on ketamine treatment for mental health with a tech-enabled GTM.
• Compass Pathways: Clinical-stage psychedelics company developing psilocybin therapy for treatment-resistant depression — addresses the same underlying patient need as Propel through a regulated, scalable clinical trial pathway.
• Mindbloom: At-home ketamine therapy provider offering guided ketamine sessions for depression and anxiety — competing for the same patient population with a different (home-based) delivery model.

Others

• Osmind: Technology platform partner to Propel providing measurement-based care, mood tracking, and out-of-network insurance claim infrastructure — adjacent enabler in the ketamine clinic ecosystem rather than a competitor.

Regional players

• Better U (ketamine clinic operator): Regional ketamine and integrative psychiatry clinic operating outside California, delivering IV ketamine protocols and psychiatry services comparable to Propel's outpatient mental health offering.

Broad incumbents

• NRx Pharmaceuticals: Pharmaceutical company commercializing SPRAVATO (esketamine) and other ketamine-adjacent therapeutics — a broader incumbent addressing the same treatment-resistant depression patient population via FDA-approved channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Propel.Therapeutics
• LinkedInlinkedin.com/company/propel-therapeutics
• Instagraminstagram.com/propel_therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Propel Therapeutics